Retatrutide Trial Shows Up to 25% Weight Loss in Obesity Drug Study
The experimental triple-hormone drug Retatrutide achieved up to 25 percent weight loss in its phase 3 clinical trial, marking a new benchmark for obesity treatments.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The odds
Each tick is a source publishing on this story
Price data
| Time | Chance of yes |
|---|---|
| now | 3% |
| 1 Oct, 21:37 UTC | 3% |
| 1 Oct, 18:12 UTC | 6% |
| 1 Oct, 06:01 UTC | 7% |
| 1 Oct, 03:19 UTC | 10% |
| 1 Oct, 01:20 UTC | 12% |
| 29 Sept, 22:38 UTC | 7% |
| 28 Sept, 22:15 UTC | 3% |
The story so far
2 publishers have covered this in 2 articles since 29 Sept 2026. Scientific American published first, on 29 September at 22:01 UTC; Ars Technica followed 30 min later. The most recent article, from Ars Technica, appeared on 29 September at 22:30 UTC.
Outlets reporting it: Ars Technica (major outlet), Scientific American.
One prediction market prices this story:
- Before Jan 1, 2027 — the market puts it at 3%, with $1k traded in the last 24 hours, closing 1 Jan 2027. The market resolves to Yes if the FDA approves retatrutide (LY3437943) for marketing before January 1, 2027. Otherwise, it resolves to No. Readers often mistake the trial results in the linked story for an approval, but only a formal FDA decision counts.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
Sources
Every article we clustered into this story. Headlines link to the publisher.
Related prediction markets
Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right
- Kalshi Before Jan 1, 2027 3% −4
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Email me when the odds move
In this story
- Retatrutide